Cerebrolysin vs Noopept
Well Studied vs Moderate Research
monitor Researched · 90% Both enhance neurotrophic factors; potential additive effects—start with lower doses.
Molecular Data
Cerebrolysin Noopept
Weight Variable 318.37 Da
Half-life Minutes (component-dependent; e.g., BDNF ~10 min) ~30 minutes (oral), active metabolite cycloprolylglycine persists longer
Chain Multiple peptides —
Type Purified porcine brain proteins Dipeptide derivative (C17H22N2O4)
Key Benefits
Cerebrolysin
01 Direct brain delivery
02 Standardized dosing
03 Extensive clinical evidence
04 Ready-to-use formulation
05 Used clinically in 50+ countries
Noopept
01 Enhanced memory formation and consolidation through upregulation of BDNF and NGF
02 Neuroprotective effects against oxidative stress, excitotoxicity, and amyloid-beta toxicity
03 Improved learning capacity and information retrieval via AMPA/NMDA receptor modulation
04 Ultra-low effective dose (10-30 mg) compared to classical racetams, reducing pill burden and cost
05 Anxiolytic properties observed at standard nootropic doses without sedation
06 Fast onset of subjective effects despite the short parent compound half-life, due to active metabolite persistence
Dosing Protocols
Cerebrolysin
10-50mL depending on indication (stroke/TBI higher doses) / Once daily for acute conditions; 5 days weekly for chronic conditions
Small Volume IV Up to 10mL Once daily
Intramuscular Up to 5mL Once daily
Acute Stroke 20-50mL Once daily for 10-21 days
Traumatic Brain Injury 20-50mL Once daily for 7-30 days
Alzheimer's Disease 10-30mL 5 days weekly for 4 weeks
Vascular Dementia 10-30mL 5 days weekly for 4 weeks
Noopept
10-30 mg/day / Split AM/PM (sublingual or oral)
Side Effects
Cerebrolysin
Generally well tolerated
Possible mild dizziness or agitation in early treatment
Noopept
Headache (most common side effect, typically caused by insufficient choline intake -- co-supplementation with Alpha-GPC or CDP-Choline usually resolves this)
Irritability and restlessness, particularly at doses exceeding 30 mg/day
Insomnia if taken too late in the day
Mild gastrointestinal discomfort when taken on an empty stomach
Contraindications
Epilepsy
Severe renal insufficiency
History of severe allergic reactions to porcine products
Known hypersensitivity to Noopept or related compounds
Severe hepatic impairment (metabolized by the liver)
Severe renal impairment
Pregnancy and breastfeeding (insufficient safety data)
Hypertension that is poorly controlled (due to potential mild pressor effects)
Research Evidence
Cerebrolysin Noopept
Status Well Studied Moderate Research
References 5 studies 4 studies
Latest 2021 —
FDA Approved No No
More comparisons: Modafinil
This comparison is for educational and research purposes only. Consult a healthcare professional before use.